ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
126.526,27
1,51%
S&P 500
5.099,96
1,02%
US Dollar vs BRL
5,1163
0,00%
Bitcoin
63.384,79
-0,56%
Brent Oil
88,165
0,00%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. Canadá
  5. TSX
  6. Trilogy International Partners Inc (TRL)

  7. Trilogy International Partners Inc (TRL) Notícias

TRL

Trilogy International Pa... (TRL)

Trilogy International Partners Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:TSX:TRL
DataHoraFonteTítuloCódigoCompanhia
07/02/202214:15PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - TRL.WTTSX:TRLTrilogy International Partners Inc
07/02/202214:12PR Newswire (Canada)IIROC Trading Halt - TRL.WTTSX:TRLTrilogy International Partners Inc
07/10/202109:18PR Newswire (Canada)L'OCRCVM permet la reprise de la négociation - TRLTSX:TRLTrilogy International Partners Inc
07/10/202109:16PR Newswire (Canada)IIROC Trade Resumption - TRLTSX:TRLTrilogy International Partners Inc
06/10/202116:10PR Newswire (Canada)Suspension de la négociation par l'OCRCVM - TRLTSX:TRLTrilogy International Partners Inc
06/10/202116:09PR Newswire (Canada)IIROC Trading Halt - TRLTSX:TRLTrilogy International Partners Inc
15/02/201920:12PR Newswire (US)Phoenix Tower International expands footprint in South America with acquisition of 600 wireless communication tower sites fro...TSX:TRLTrilogy International Partners Inc
08/09/201718:45PR Newswire (Canada)S&P Dow Jones Indices Announces Changes to the S&P/TSX Canadian IndicesTSX:TRLTrilogy International Partners Inc
08/09/201718:42PR Newswire (Canada)S&P Dow Jones Indices annonce des modifications aux indices canadiens S&P/TSXTSX:TRLTrilogy International Partners Inc
16/03/201508:30PR Newswire (Canada)Endo Pharmaceuticals Announces the Launch of NATESTO™ (testosterone nasal gel), the First and Only Nasal Gel for Testostero...TSX:TRLTrilogy International Partners Inc
09/12/201410:00PR Newswire (Canada)Endo Completes Acquisition of Rights to Natesto™ Testosterone Nasal GelTSX:TRLTrilogy International Partners Inc
01/12/201411:34InvestorsHub NewsWireEDISON EQUITY RESEARCH - TRIMEL PHARMACEUTICALSTSX:TRLTrilogy International Partners Inc
06/08/201401:27InvestorsHub NewsWireTrimel Pharmaceuticals - Seeking positive EBITDA with EstraceTSX:TRLTrilogy International Partners Inc
30/07/201410:15Marketwired CanadaTrimel Completes Private Placement of Common SharesTSX:TRLTrilogy International Partners Inc
28/07/201411:12InvestorsHub NewsWireTrimel Pharmaceuticals - A closer look at Tefina Phase II FOD resultsTSX:TRLTrilogy International Partners Inc
25/07/201419:31PR Newswire (Canada)Update to Early Warning Report for Trimel Pharmaceuticals CorporationTSX:TRLTrilogy International Partners Inc
17/07/201414:53PR Newswire (Canada)L’OCRCVM permet la reprise de la négociation - TRLTSX:TRLTrilogy International Partners Inc
17/07/201414:40Marketwired CanadaTrimel Pharmaceuticals Acquires Canadian Rights to Estrace®TSX:TRLTrilogy International Partners Inc
18/06/201416:00MarketwiredTrimel to Present at the JMP Securities Healthcare ConferenceTSX:TRLTrilogy International Partners Inc
16/06/201416:20MarketwiredTrimel to Present at the 2014 Bloom Burton & Co. Healthcare Investor ConferenceTSX:TRLTrilogy International Partners Inc
16/06/201407:00MarketwiredTrimel Reports Additional Results From Tefina(TM) Phase II Clinical TrialTSX:TRLTrilogy International Partners Inc
12/06/201420:41MarketwiredTrimel Announces Voting Results for 2014 Annual General and Special Shareholders' MeetingTSX:TRLTrilogy International Partners Inc
28/05/201422:06PR Newswire (US)Trimel Receives FDA Approval for Natesto(TM) Nasal Gel to Treat Men with Low TestosteroneTSX:TRLTrilogy International Partners Inc
28/05/201420:28PR Newswire (Canada)Trimel Receives FDA Approval for Natesto™ Nasal Gel to Treat Men with Low TestosteroneTSX:TRLTrilogy International Partners Inc
28/05/201407:30PR Newswire (US)Trimel Pharmaceuticals Announces Positive Phase II Results for Tefina™TSX:TRLTrilogy International Partners Inc
08/05/201418:29MarketwiredTrimel Provides Corporate Update and First Quarter 2014 Financial ResultsTSX:TRLTrilogy International Partners Inc
02/05/201416:37MarketwiredTrimel to Report First Quarter 2014 Results and Host Conference Call to Update InvestorsTSX:TRLTrilogy International Partners Inc
05/03/201421:33MarketwiredTrimel Reports Fourth Quarter and Full Year 2013 Financial ResultsTSX:TRLTrilogy International Partners Inc
27/02/201418:45MarketwiredTrimel to Report Financial Results for 2013 and Host Conference Call to Update InvestorsTSX:TRLTrilogy International Partners Inc
21/02/201417:44MarketwiredTrimel Announces Closing of $10.5 Million Private Placement of Common SharesTSX:TRLTrilogy International Partners Inc
 Apresentando as notícias mais relevantes sobre:TSX:TRL

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
MATD3
Hospital Mater Dei S.A ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
GOLL4
GOL PN
BOV
PDTC3
Padtec ON
BOV
OIBR3
OI ON
BOV
PDGR3
PDG REALT ON
BOV
HOOT4
HOTEIS OTHON PN
BOV
UNIP6
UNIPAR PNB
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados